RE:RE:Is there a trading halt on TST???
If I had to guess I would say that the analysts will not issue the reports until the trading situation with the name change is in order and maybe not release them until January when the market size analysis is complete. if the company is successful getting a fast track evaluation the marketing approval could potentially fall within the 12 month target of the reports. That would be a very interesting analysis on a stock with this puny market cap. since no one including the company or the FDA can say whether the patient size is below 10,000 or over 200K the target share price could vary wildly. I would think that before these reports will reflect the findings on market size that Bioniche has contracted. This report was said to be ready before year end. I am not sure how the analysts can explain the current market cap. I guess they will say that the company has a terrible history of driving value in its share price but even then it will seem unusual. The Seeking Alpha analyst did a good job by just calling it 'under the radar" The better thing would be to not even discuss the past few years in any length including 2014.